ClinicalTrials.gg
RecruitingNCT07584824Updated May 13, 2026

Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?

An observational study in Cancer, Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative and Cancer (Solid Tumors), sponsored by Royal Cornwall Hospitals Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Royal Cornwall Hospitals Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The 1939 Cancer Act in the UK (England \& Wales) prohibits advertising of cancer treatments to the public, by anyone but the NHS. The rise of the internet and social media presents new challenges to its enforcement and raises questions about unintended consequences for patients being treated for cancer.

Through anonymous surveys, this study aims to understand how patients, healthcare professionals and industry professionals perceive technological changes and their implications for online and social media cancer care information, as well as highlight opportunities for safe and ethical modernisation.

Read the detailed description

This study will be inviting patients who have recently received treatment for cancer to participate in a single survey, about their experiences of online and social media information during their cancer journey and their views on the current law. Healthcare professionals who work with cancer patients will also be invited to participate in their own variation of this survey.

02

Conditions studied

  • Cancer
  • Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
  • Cancer (Solid Tumors)
  • Cancer (With or Without Metastasis)
  • Cancer (Advanced Stage)

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 50 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Royal Cornwall Hospitals Trust is the lead sponsor of 24 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults geographically resident in England or Wales, who have recent experience in receiving or providing cancer treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients/Relatives:

  • UK residents (England and Wales ONLY).
  • Have been treated for a cancer within the last three years.
  • Aged 18 or over.
  • Can complete the survey themselves or have it completed on their behalf by a friend or family member (with the patient's permission).

Healthcare Professionals:

  • UK-based professionals in the healthcare industry.
  • Working with patients diagnosed with cancer.
  • Consulting with patients at least once a month or more frequently.
  • Aged 18 or over.

Exclusion criteria

Exclusion Criteria:

No explicit exclusion criteria are defined within provided materials, therefore any individual not meeting the inclusion criteria will be excluded.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient participants- UK residents (England and Wales ONLY).

    * Aged 18 or over. * Have been treated for a cancer within the last three years. * Can complete the survey themselves or have it completed on their behalf by a friend or family member (with the patient's permission).

  • Healthcare Professionals (UK-based professionals in the healthcare industry.)

    * Aged 18 or over. * Working with patients diagnosed with cancer. * Consulting with patients at least once a month or more frequently.

06

What researchers measure

Primary outcomes

  1. Is the 1939 Cancer Act fit for purpose in the current digital era?

    The survey uses factual single-choice items, multiple-response items and mainly Likert-scale attitude questions. Themes of questions and reported outcomes are: * Current use of online information for cancer: report descriptively. * Reasons for not using online/social media information. Report proportions and themes of free-text question. * Private healthcare information access. Report descriptively. Following outcomes will have numerically-codes Likert scales with report of mean and standard deviation: * Perceived adequacy of cancer information * Confidence in evaluating online cancer information * Attitudes toward the Cancer Act 1939. Support for modernising the Cancer Act, Attitudes toward direct-to-patient advertising and advertising of alternative treatments * Views on digital misinformation issues Overall view on reform. Assesses whether the Cancer Act needs reform; treat as an ordinal outcome with statistical testing (Kruskall Wallis test, P value, SD).

    Time frame: The study will be open for 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2026, 4 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 4 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 13, 2026
StartActual
Jan 9, 2026
Primary completionEst.
May 30, 2026
CompletionEst.
May 30, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07584824
Lead sponsor
Royal Cornwall Hospitals Trust
Collaborators
University of Warwick
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Jan 9, 2026
Primary completion
May 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
May 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion